- Investing.com
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Brand Powe | Learn how Kenvue leverages its portfolio of established brands to potentially expand market share and capitalize on emerging trends in consumer health |
Financial Outlook | Analysts project EPS around $1.15, with price targets ranging from $21 to $27. Management aims for 3-4% sales growth and a 3.5% dividend yield |
Market Challenges | Delve into Kenvue's struggle to maintain market share, particularly in the Skin Health & Beauty segment, amid fierce competition in consumer health |
Strategic Shift | Explore Kenvue's "Extraordinary Powers" strategy, designed to drive growth and operational efficiency as the company navigates its first year of independence |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
---|---|---|---|---|
P/E Ratio | 43.6x | 24.6x | 11.6x | |
PEG Ratio | −1.49 | 0.72 | 0.03 | |
Price / Book | 4.6x | 3.2x | 1.5x | |
Price / LTM Sales | 3.0x | 2.1x | 0.9x | |
Upside (Analyst Target) | 0.7% | 43.0% | 18.0% | |
Fair Value Upside | Unlock | 1.3% | 10.6% | Unlock |